Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) Antibody

195€ (20 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx007073
tested applications
ELISA, WB, IP
Description
AKR1B10 Antibody is a Rabbit Polyclonal Antibody against AKR1B10.
Documents del producto
Instrucciones
Data sheet
Product specifications
Category | Primary Antibodies |
Immunogen Target | Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) |
Host | Rabbit |
Reactivity | Human, Mouse, Rat |
Recommended Dilution | ELISA: 1 µg/ml, WB: 1/500 - 1/2000. Optimal dilutions/concentrations should be determined by the end user. |
Clonality | Polyclonal |
Conjugation | Unconjugated |
Isotype | IgG |
Purification | Purified by affinity chromatography. |
Size 1 | 20 µl |
Size 2 | 100 µl |
Size 3 | 2 × 100 µl |
Form | Liquid |
Tested Applications | ELISA, WB, IP |
Buffer | PBS, pH 7.3, containing 0.02% sodium azide, 50% glycerol. |
Availability | Shipped within 5-10 working days. |
Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
Dry Ice | No |
UniProt ID | O60218 |
Gene ID | 57016 |
NCBI Accession | NP_064695.3 |
Alias | AKR1B10,AKR1B11,AKR1B12,ALDRLn,ARL-1,ARL1 |
Background | Antibody anti-AKR1B10 |
Status | RUO |
Note | Concentration: > 0.2 mg/ml - |
Descripción
AKR1B10 is primarily expressed in the liver, intestines, and lungs, where it catalyzes the reduction of carbonyl compounds, including aldehydes derived from lipid peroxidation and retinoic acid metabolism. AKR1B10 plays a pivotal role in detoxifying reactive aldehydes, thereby protecting cells from oxidative stress and lipid damage. It also regulates cellular retinoic acid levels, influencing cell proliferation, differentiation, and apoptosis. Overexpression of AKR1B10 is strongly associated with various cancers, particularly hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), and colorectal cancer, where it enhances tumor progression, chemoresistance, and metastasis. AKR1B10 contributes to drug resistance by metabolizing chemotherapeutic agents and supporting lipid synthesis for tumor growth. Its role in fatty acid biosynthesis links it to metabolic reprogramming in cancer cells, promoting proliferation and survival. AKR1B10 is considered a promising biomarker for cancer diagnosis and prognosis, as well as a therapeutic target for improving cancer treatment outcomes.
Related Products

Human AKR1B10(Aldo-keto reductase family 1 member B10) ELISA Kit
Ver Producto
Recombinant Human akr1b10
Ver Producto